在核心结合因子急性髓性白血病中,强化诱导方法的现实结果
Alexandra E Rojek1, Benjamin J McCormick2, Joanna Cwykiel3
1Department of Medicine Section of Hematology/Oncology University of Chicago Chicago Illinois USA.
EJHaem
|August 19, 2024
概括
加入密集化疗 (IC) 的gemtuzumab ozogamicin (GO) 并没有改善核心结合因子急性髓性白血病 (CBF-AML) 患者的结果. 然而,IC与KIT抑制剂相结合,在CBF-AML中显著提高了无事件生存率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 核心结合因子急性髓性白血病 (CBF-AML) 是一个有利风险的亚型.
- 吉姆图祖马布 (Gemtuzumab ozogamicin,GO) 是一种针对CD33的抗体-药物结合物,通常与强化化疗 (IC) 一起使用.
研究的目的:
- 为了比较CBF-AML患者的治疗结果,这些患者接受了具有或没有GO的IC.
- 评估IC加KIT抑制剂与具有或没有GO的IC的疗效.
主要方法:
- 来自七个学术中心的200名CBF-AML患者的回顾性分析.
- 治疗组:单独使用IC,使用GO的IC,使用KIT抑制剂 (达沙替尼或中素) 的IC.
- 三年总生存率 (OS) 和无事件生存率 (EFS) 的比较.
主要成果:
- 在3年EFS (50%与47%相比) 或IC与GO和IC单独之间没有显著差异.
- 接受IC加KIT抑制剂的患者显示,与具有或没有GO的IC相比,3年EFS (85%) 显著改善 (p=0.04).
结论:
- 将GO添加到IC中不会在CBF-AML中产生生存益处.
- 与KIT抑制剂结合的IC显示在CBF-AML患者中改善了EFS.
- 这些发现支持进一步研究CBF-AML治疗范式中的KIT抑制剂.
相关概念视频
Bone Marrow Sampling and Transplants
317
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
317
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K


